MediPal Holdings Corporation
Full-year Earnings Forecast Revision ｜ Medipal Holdings July 14, 2026
Medipal Holdings Corporation revised its full-year consolidated earnings forecast for the fiscal year ending March 2027, announced on May 14, 2026. Revenue remains unchanged at 3,944,000 hundred million yen, while net profit has been upwardly revised to 43,000 hundred million yen. The increase in profit is primarily due to the impact of making PALTACT Co., Ltd. a wholly owned subsidiary through share acquisition.
Key Figures
- Revenue: 3,944,000 hundred million yen (no change)
- Net income attributable to owners of the parent: 43,000 hundred million yen (YoY +10.3%)
- Operating income: 53,500 hundred million yen (△1,500 hundred million yen)
AI要約
Performance Overview
Medipal Holdings Corporation has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027, maintaining revenue at 3,944,000 hundred million yen as previously estimated, and upwardly revising net income to 43,000 hundred million yen. This increase is mainly due to the profit attributable to the full acquisition of PALTACT Co., Ltd., though related expenses and financial costs are also expected to rise.
Future Outlook and Impact on Shareholders
The full acquisition of shares has resulted in all profit previously attributable to non-controlling shareholders now being attributable to the Company, contributing to the increase in net income. However, temporary costs and expenses are also anticipated, requiring close monitoring of their impact on performance. The Company will continue to actively pursue M&A as part of its business strategy.
Medipal Holdings Corporation
Company overview · Stock price · Financial data · All IR
